Jahannaz Dastgir, DO

Title: Clinical Development Lead REGENXBIO

Bio: Jahannaz Dastgir, DO is a pediatric neuromuscular specialist and the clinical development lead of the RGX-202 program at Regenxbio. This program focuses on AAV8 gene therapy for Duchenne Muscular Dystrophy.

2023 FUTURES: Gene Therapy and Gene Editing Sessions

A brief primer on the gene therapy and gene editing approach to treating Duchenne, and updates from relevant companies in the space. These presentations will be followed by a moderated Q&A opportunity.

Alison Mcvie-Wylie, PhD

Vice President, Disease Area Executive, DMD

Vertex Pharmaceutical

See more from same speaker

Jahannaz Dastgir, DO

Clinical Development Lead REGENXBIO

See more from same speaker

Patrick Gonzalez, PhD

Senior Director of Clinical Science Solid Biosciences

See more from same speaker

Teji Singh, MD

Vice President, Head of Clinical Development Sarepta Therapeutics

See more from same speaker

Dan Levy, MD

VP and Development Head, Rare Neurology Pfizer

See more from same speaker

Video
Share this:
Beginning the Journey - diagnosed 0-3 yearsGrowth and Transformation - diagnosed 3-6 yearsSpreading Wisdom - diagnosed 6+ years

2024 FUTURES GENE Therapy panel

Gene Therapy Approaches to Treatment We covered the rationale behind gene therapy approaches for Duchenne and received updates from Pfizer, Sarepta Therapeutics, REGENXBIO Inc., and Solid BioSciences.

Michael Kelly, PhD

Chief Scientific Advisor

CureDuchenne

See more from same speaker

Jahannaz Dastgir, DO

Clinical Development Lead REGENXBIO

See more from same speaker

Patrick Gonzalez, PhD

Senior Director of Clinical Science Solid Biosciences

See more from same speaker

Robyn van Poelgeest, MD, PhD

Sarepta

See more from same speaker

Video
Share this:
Beginning the Journey - diagnosed 0-3 yearsGrowth and Transformation - diagnosed 3-6 yearsSpreading Wisdom - diagnosed 6+ years